Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pneumococcal Meningitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Pneumococcal Meningitis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-001707-38 Sponsor Protocol Number: PN-0709 Start Date*: 2007-07-31
    Sponsor Name:University Hospital
    Full Title: A phase IIIb, open, controlled study to evaluate the immunogenicity, and safety of 7PCV Prevenar vaccine in pre-term infants
    Medical condition: Premature children suffer from large variety of different accompanying diseases. Pneumoccocal diseases creates substantial proportion especially in children with undergoing diseases of respiratory ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054047 Pneumococcal sepsis LLT
    9.1 10027253 Meningitis pneumococcal LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002888-18 Sponsor Protocol Number: CHAVANET-PHRC-2016 Start Date*: 2018-01-16
    Sponsor Name:CHU Dijon Bourgogne
    Full Title: Adjunction of daptomycin for the treatment of pneumococcal meningitis AddaMAP study
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027253 Meningitis pneumococcal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004542-18 Sponsor Protocol Number: V114-002 Start Date*: 2012-04-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ™ 23) and ...
    Medical condition: prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, 1, 5, 7F, 3, 6A, 19A, 22F,...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10035728 Pneumonia pneumococcal PT
    14.1 10021881 - Infections and infestations 10054047 Pneumococcal sepsis PT
    14.1 10021881 - Infections and infestations 10058886 Pneumococcal bacteremia LLT
    14.1 10021881 - Infections and infestations 10027253 Meningitis pneumococcal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023919-34 Sponsor Protocol Number: INFSNC1 Start Date*: 2011-03-17
    Sponsor Name:María Carmen Cabellos Mínguez
    Full Title: Estudio de la eficacia de la fenitoína en la profilaxis de las convulsiones en los pacientes con meningitis neumocócica de 50 años o más. Ensayo clínico comparativo, multicéntrico, controlado con p...
    Medical condition: Profilaxis de convulsiones en meningitis neumocócica
    Disease: Version SOC Term Classification Code Term Level
    13 10027253 Meningitis neumocócica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017498-39 Sponsor Protocol Number: OVG2009/4 Start Date*: 2010-03-18
    Sponsor Name:University of Oxford
    Full Title: A follow-on, multi-centre, open-label, clinical, phase 3 trial to investigate the persistence of serotype-specific antibodies at 40 months of age in children who have received either the 7-valent o...
    Medical condition: Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks to 5 years of age.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10042193 Streptococcus pneumoniae acute exacerbation of chronic bronchitis LLT
    12.1 10042194 Streptococcus pneumoniae meningitis LLT
    12.1 10042195 Streptococcus pneumoniae pneumonia LLT
    12.1 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    12.1 10042197 Streptococcus pneumoniae septicaemia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015103-58 Sponsor Protocol Number: V114-001 Start Date*: 2010-01-14
    Sponsor Name:MSD Finland Oy
    Full Title: A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar™ in Healthy Adults and Toddlers
    Medical condition: Prevention of pneumococcal invasive disease, pneumococcal pneumonia, and otitis media caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, 1, 5, 7F, 3...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10054047 Pneumococcal sepsis LLT
    12.1 10058886 Pneumococcal bacteremia LLT
    12.1 10027253 Meningitis pneumococcal LLT
    12.1 10035647 Pneumococcal pneumonia LLT
    12.1 10033079 Otitis media acute LLT
    Population Age: Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-022303-22 Sponsor Protocol Number: B1851047 Start Date*: 2011-06-22
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO ASSESS THE IMPACT OF PROPHYLACTIC ANTIPYRETIC MEDICATION ON THE IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH ROUTINE PEDIATRIC VA...
    Medical condition: Pneumonia and ear infections caused by S pneumoniae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10042194 Streptococcus pneumoniae meningitis LLT
    14.1 10021881 - Infections and infestations 10042195 Streptococcus pneumoniae pneumonia LLT
    14.1 10021881 - Infections and infestations 10042197 Streptococcus pneumoniae septicaemia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005743-27 Sponsor Protocol Number: 116485,SPNG-009 Start Date*: 2012-05-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccines (2830929A and 2830930A) adminis...
    Medical condition: 3-dose primary vaccination against Streptococcus pneumoniae and Haemophilus influenzae in healthy infants between 6-12 weeks of age at the time of the first vaccination and booster vaccination at 1...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    14.1 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    14.1 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    14.1 100000004862 10042194 Streptococcus pneumoniae meningitis LLT
    14.1 100000004862 10018954 Haemophilus influenzae secondary bacterial infection of acute bronchitis LLT
    14.1 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    14.1 100000004862 10018953 Haemophilus influenzae meningitis LLT
    14.1 100000004862 10018952 Haemophilus influenzae infection LLT
    14.1 100000004862 10058214 Septicaemia due to haemophilus influenzae (H. influenzae) LLT
    14.1 100000004862 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002727-15 Sponsor Protocol Number: 114174 Start Date*: 2015-06-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-type...
    Medical condition: Healthy volunteers (for one-dose vaccination of healthy children between 2-4 years of age at the time of vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    18.0 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    18.0 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    18.0 100000004862 10018954 Haemophilus influenzae secondary bacterial infection of acute bronchitis LLT
    18.0 100000004862 10042194 Streptococcus pneumoniae meningitis LLT
    18.0 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    18.0 100000004862 10018953 Haemophilus influenzae meningitis LLT
    18.0 100000004862 10018952 Haemophilus influenzae infection LLT
    18.0 100000004862 10058214 Septicaemia due to Haemophilus influenzae (H. influenzae) LLT
    18.0 100000004862 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019775-29 Sponsor Protocol Number: V114-003 Start Date*: 2010-09-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: "Estudio multicéntrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con Prevenar 13™ en lactantes sanos";"A Mul...
    Medical condition: Prevención de la enfermedad invasiva neumocócica, la neumonía neumocócica y la otitis media causada por S. pneumoniae, debido a los serotipos capsulares incluidos en la vacuna (4, 6B,9V,14,18C,19F,...
    Disease: Version SOC Term Classification Code Term Level
    13 10054047 Sepsis neumocócica LLT
    13 10058886 Bacteriemia por neumococo LLT
    13 10027253 Meningitis neumocócica LLT
    13 10035647 Neumonía neumocócica LLT
    13 10033078 Otitis media LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002225-22 Sponsor Protocol Number: 115373 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I, randomized, controlled, double-blind study to assess safety, reactogenicity and immunogenicity of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in hea...
    Medical condition: 1-dose vaccination of healthy toddlers between 12-23 months of age at the time of vaccination against Streptococcus pneumoniae (S. pn) and Haemophilus influenzae (Hi) who previously received 3 dose...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10018953 Haemophilus influenzae meningitis LLT
    14.0 10021881 - Infections and infestations 10042194 Streptococcus pneumoniae meningitis LLT
    14.0 10021881 - Infections and infestations 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    14.0 10021881 - Infections and infestations 10018954 Haemophilus influenzae secondary bacterial infection of acute bronchitis LLT
    14.0 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    14.0 10021881 - Infections and infestations 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    14.0 10021881 - Infections and infestations 10054642 Streptococcus pneumoniae septicemia LLT
    14.0 10021881 - Infections and infestations 10042195 Streptococcus pneumoniae pneumonia LLT
    14.0 10021881 - Infections and infestations 10058214 Septicaemia due to haemophilus influenzae (H. influenzae) LLT
    14.0 10021881 - Infections and infestations 10042197 Streptococcus pneumoniae septicaemia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002898-47 Sponsor Protocol Number: 107737 Start Date*: 2007-01-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb open study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-HBV-IPV/Hib (Infanrix h...
    Medical condition: Three dose primary vaccination of preterm infants between 8-16 weeks (56-118 days) of age at the time of first vaccination against Streptococcus pneumoniae.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-016579-31 Sponsor Protocol Number: OVG2008/6 Start Date*: 2010-01-14
    Sponsor Name:University of Oxford
    Full Title: An open label randomised controlled study to evaluate the induction of immune memory following infant vaccination with a glyco-conjugate Neisseria meningitidis serogroup C vaccine and to assess the...
    Medical condition: Active immunisation of children for the prevention of invasive diseases caused by Neisseria meningitidis serogroup C, Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and inv...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028911 Neisseria meningitidis infection NOS LLT
    12.1 10042194 Streptococcus pneumoniae meningitis LLT
    12.1 10042195 Streptococcus pneumoniae pneumonia LLT
    12.1 10035648 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] LLT
    12.1 10042197 Streptococcus pneumoniae septicaemia LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10018953 Haemophilus influenzae meningitis LLT
    12.1 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    12.1 10058214 Septicaemia due to haemophilus influenzae (H. influenzae) LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007535-23 Sponsor Protocol Number: PUNS Start Date*: 2008-10-01
    Sponsor Name:St George's University of London
    Full Title: A phase IV study to evaluate the primary and booster immune responses of UK preterm infants receiving licensed DTaP/Hib/IPV and meningococcal C conjugate vaccine and incorporating a randomisation s...
    Medical condition: These are vaccines routinely given to infants in the UK and are not administered with respect to existing medical condition(s), rather in the prevention of diseases.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001592-30 Sponsor Protocol Number: V72P12 Start Date*: 2008-06-11
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with...
    Medical condition: The Novartis Meningococcal B Recombinant + OMV NZ Vaccine is intended for prevention of meningitidis and/or septicemia caused by N.meningitidis serogroup B. The objective of the Novartis Meningococ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027276 Meningococcal meningitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-005102-30 Sponsor Protocol Number: OVG2011/05 Start Date*: 2011-12-08
    Sponsor Name:University of Oxford
    Full Title: A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vacci...
    Medical condition: The study will include healthy children who have already been vaccinated with 2 doses of Prevenar 13 according to the UK routine immunisation schedule at 2 and 4 months of age. Both vaccines used i...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002352-18 Sponsor Protocol Number: 103813,105067 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of...
    Medical condition: Invasive disease caused by Haemophilus type b and Neisseria meningitidis serogroups C and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.0 100000004862 10051931 Neisseria infection NOS LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004056-36 Sponsor Protocol Number: Sched2 Start Date*: 2007-12-20
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses ...
    Medical condition: All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against: Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), H...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027274 Meningococcal infection PT
    9.1 10061353 Pneumococcal infection LLT
    9.1 10013023 Diphtheria LLT
    9.1 10043376 Tetanus LLT
    9.1 10034738 Pertussis LLT
    9.1 10018955 Haemophilus meningitis LLT
    9.1 10036008 Polio LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001505-14 Sponsor Protocol Number: 110808 Start Date*: 2015-06-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, controlled, single-blind study to evaluate the non-inferiority of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate vaccine compared to the 7-valent pneumococca...
    Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae and Haemophilus influenzae t...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    18.0 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    18.0 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    18.0 100000004862 10035648 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003761-16 Sponsor Protocol Number: 9818P Start Date*: 2005-11-24
    Sponsor Name:Department of R & D, Central Manchester and Manchester Children's Hospital NHS Trust
    Full Title: Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia
    Medical condition: Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This l...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA